Skip to main content

Peer Review reports

From: Cost-effectiveness analysis of pembrolizumab in combination with chemotherapy compared with chemotherapy alone as first-line treatment for patients with advanced biliary tract cancer in China

Original Submission
25 May 2023 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
18 Jul 2023 Reviewed Reviewer Report
24 Jul 2023 Reviewed Reviewer Report
25 Jul 2023 Reviewed Reviewer Report
27 Jul 2023 Author responded Author comments - Zhiwei Zheng
Resubmission - Version 3
27 Jul 2023 Submitted Manuscript version 3
31 Jul 2023 Author responded Author comments - Zhiwei Zheng
Resubmission - Version 4
31 Jul 2023 Submitted Manuscript version 4
Publishing
4 Aug 2023 Editorially accepted
4 Sep 2023 Article published 10.1186/s12885-023-11255-w

You can find further information about peer review here.

Back to article page